Polypeptide for targeted inhibition of SLUG transcriptional activation and use thereof

By designing a polypeptide and its derivative that can specifically bind to SLUG, blocking ZNF451 to promote CCL5 transcriptional activation, solving the problem of drug lacking effective targeting ZNF451 protein in the prior art, and achieving tumor cell growth and metastasis Effective inhibition, with significant therapeutic effect and safety.

CN116253775BActive Publication Date: 2024-11-05INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111504729.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-10
Publication Date
2024-11-05
Estimated Expiration
2041-12-10

AI Technical Summary

Technical Problem

There is a lack of effective targeted drugs in the prior art to block the interaction between ZNF451 and SLUG and inhibit the growth, metastasis and invasion of tumor cells. In particular, targeted drugs targeting the ZNF451 protein have not been reported.

Method used

Provide a polypeptide and its derivatives that can specifically bind to SLUG, block ZNF451 to promote CCL5 transcriptional activation, inhibit the growth, metastasis and invasion of tumor cells, and form chimeric peptides through ligation with cell membrane penetration peptides to improve membrane penetration ability. .

Benefits of technology

This polypeptide can significantly inhibit the interaction between ZNF451 and SLUG, downregulate CCL5 expression, slow down the migration and growth of tumor cells, has significant efficacy and high safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003402879760000071
    Figure BDA0003402879760000071
  • Figure BDA0003402879760000081
    Figure BDA0003402879760000081
  • Figure HDA0003402879770000011
    Figure HDA0003402879770000011
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine, and discloses a polypeptide for targeted inhibition of SLUG transcriptional activation and its use, and specifically discloses a polypeptide or a polypeptide derivative for targeted inhibition of SLUG transcriptional activation, and its use in a drug for treating cancer. The present invention discloses that the amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1, and the polypeptide has the ability to specifically bind to SLUG and block the binding of SLUG and ZNF451 protein, thereby inhibiting the transcriptional regulation of SLUG on CCL5; the present invention also discloses that the polypeptide derivative is a chimera formed by the combination of the polypeptide and the cell-penetrating peptide, wherein the amino acid sequence of the cell-penetrating peptide is as shown in SEQ ID NO: 2, and the polypeptide and its polypeptide derivative have the advantages of significant efficacy, few toxic side effects, and safe use in the treatment of tumor diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a polypeptide and a polypeptide derivative thereof and application thereof in preparing a drug for treating cancer. Background Art

[0002] ZNF451 is a vertebrate zinc finger protein that acts as a transcriptional co-regulator and is partially localized in promyelocytic leukemia bodies. It can be modified by ubiquitination (SUMO), and this SUMO modification is necessary for its localization in promyelocytic leukemia bodies. As a product gene of promyelocytic leukemia, it is involved in regulating cell differentiation, cell senescence, cell apoptosis, immune response and DNA repair. The structure of ZNF451 contains two predicted SIM motifs, twelve C2H2 zinc finger domains, and ubiquitin interaction motifs. Our study found that ZNF451 protein expression increased in a variety of tumors, and overexpression of ZNF451 can increase the expression of chemokine CCL5. Further studies confirmed that ZNF451 enhances SLUG transcriptional activation of CCL5 by binding to SLUG protein, and plays a promoting role in tumorigenesis, tumor proliferation, tumor metastasis, and tumor resistance.

[0003] Chemokines are a class of small cytokines or signaling proteins secreted by cells. They have a relatively small molecular weight and are produced and secreted by a variety of cells. The chemokine ligand family has 48 characteristic members. According to the different conserved cysteine ​​residues at the N-terminus, chemokines can be divided into four categories: CC, CXC, CX3C and C. The CC type is also known as the chemokine subfamily. The structural feature is that the first and second cysteines are closely connected. CC chemokines mainly act on monocytes and lymphocytes, and can also promote the migration of other types of cells, such as dendritic cells (DCs), natural killer cells (NK cells), eosinophils, basophils, etc. CXC-type chemokines are characterized by an additional amino acid between the first and second cysteines. CXC chemokines are expressed on the cell surface supported by a mucin stem-like structure and can promote the migration and chemotaxis of neutrophils. CX3C-type chemokines have three additional amino acids between the first and second cysteines. The main member is neurochemotactic protein, also known as Fractalkine (FKN). The protein exists in two forms: membrane-bound and free. The membrane-bound FKN can be cleaved by the converting enzyme (TACE) to obtain the free FKN, which performs the function of chemotactic cells. C-type chemokines, this protein has only two cysteine ​​residues, forming a disulfide bond. Lymphocyte chemokine belongs to this type of chemokine, which is produced by thymocytes and activated CD8 +T cell production can induce chemotaxis of T cells and bone marrow cells, but has no effect on monocytes. Chemokines play a central role in the development of the immune system and the stability of the internal environment, and are involved in all protective or destructive immune and inflammatory responses. In the development of tumors, they are more of a multifunctional mediator that not only affects the infiltration of immune cells into tumors, but also has an important impact on tumor growth, angiogenesis, and invasion and metastasis. Changes in the expression level of chemokines in the tumor microenvironment will inevitably change the number of immune cells infiltrating into tumor tissues. For example, CC-type chemokines, the number of lymphocytes in breast cancer lesions is positively correlated with the number of tumor cells expressing CCL2 and CCI5; CCL5 can recruit CCR5 + Th1 cells accelerate the formation of an immunosuppressive microenvironment, etc.

[0004] Studies have reported that CCL5 / CCR5 plays an important role in tumor metastasis, invasion, and regulation of tumor cell stemness. At present, targeted inhibitors for this pathway mainly include small molecule drugs, antibody drugs, RNA interference drugs, and natural products. However, in the more than 30 years of research, except for a few drugs that have entered clinical trials, most drugs are still in preclinical research, and no targeted drugs with significant effects have been marketed. For example, the CCL5 humanized monoclonal antibody Pro-140 (leronlimab) developed by CytoDyn is undergoing phase II human clinical trials for metastatic triple negative breast cancer (TNBC); and the CCR5 molecular inhibitor Maraviroc is undergoing phase I clinical trials for the treatment of metastatic colon cancer; drugs targeting CCL5 / CCR5 for the treatment of gliomas are also under study. However, the research on the target function of antibody drugs is not detailed enough, the distribution of target locations is unclear, and the cross-reaction between the drug itself and non-target sites is not fully understood, so there may be serious adverse reactions in clinical practice. ZNF451 is an important protein in the process of tumor development, but there are currently no reports of drugs targeting this protein. Summary of the invention

[0005] The technical problem solved by the present invention is that the pathogenesis of malignant tumors is complex and there is a lack of effective therapeutic drugs. The present invention provides a polypeptide that interrupts the interaction between ZNF451 and SLUG and thereby blocks the transcriptional activation of the chemokine CCL5, inhibits tumor growth, metastasis and invasion, and its use in the preparation of products for treating tumors. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1.

[0006] The amino acid sequence of the present invention also includes oligopeptide sequences that have amino acid substitutions, deletions or additions at other positions and can specifically bind to SLUG. The polypeptide of the present invention and its derivatives are used for targeted treatment of diseases associated with SLUG.

[0007] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions.

[0008] The first aspect of the technical solution of the present invention is to provide a polypeptide and a polypeptide derivative thereof that can specifically bind to SLUG to target and inhibit ZNF451 from promoting CCL5 transcriptional activation, characterized in that the amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO: 1, or a sequence with the same function obtained by replacing, deleting or adding amino acids at any position thereof; the polypeptide derivative is a chimeric peptide formed by connecting the polypeptide with a cell-penetrating peptide (a cell-penetrating peptide is a type of short peptide that can carry macromolecules into cells, and its membrane-penetrating ability does not rely on classical endocytosis).

[0009] The cell-penetrating peptide is HLYVSPW (as shown in SEQ ID NO: 2 in the sequence table), and the cell-penetrating peptide is named pep2. Further, the N-terminus or C-terminus of the polypeptide PZ is connected to the cell-penetrating peptide to obtain the chimeric peptide.

[0010] The second aspect of the technical solution of the present invention is to provide the use of the polypeptide and its polypeptide derivatives described in the first aspect of the technical solution of the present invention in the preparation of drugs for targeted inhibition of ZNF451-promoted CCL5 transcriptional activation, as well as the use of the polypeptide in the preparation of drugs for treating cancer.

[0011] The "treatment" mentioned in the present invention refers to conventional treatment in the art, preferably refers to reducing the extent of the tumor, or curing the tumor to normalize it, or slowing down the progression of the tumor.

[0012] Furthermore, the drug is any one of the following:

[0013] (1) a drug that targets and inhibits the transcriptional activation activity of the SLUG protein;

[0014] (2) drugs that inhibit CCL5 transcriptional activity;

[0015] (3) Drugs that inhibit the growth of cancer cells;

[0016] (4) Drugs that reduce the stemness of cancer cells;

[0017] (5) Drugs that inhibit cancer cell migration.

[0018] Furthermore, the drug for targeted inhibition of the transcriptional activation activity of the SLUG protein is: a drug for targeted inhibition of the transcriptional activation activity of the SLUG protein that can specifically bind to SLUG.

[0019] Furthermore, the cancer is breast cancer, liver cancer, lung cancer, glioma or colon cancer.

[0020] Furthermore, the breast cancer is non-invasive breast cancer, early invasive breast cancer, invasive special type breast cancer or invasive non-special type breast cancer; the liver cancer is primary liver cancer or secondary liver cancer; the lung cancer is non-small cell lung cancer or small cell lung cancer; the glioma is astrocytoma, oligodendrocytoma, ependymoma, mixed glioma; the intestinal cancer is colon cancer or rectal cancer.

[0021] The third aspect of the technical solution of the present invention is to provide a pharmaceutical composition, which contains the polypeptide and its polypeptide derivatives that can specifically bind to SLUG and target the inhibition of ZNF451 to promote CCL5 transcriptional activation as active ingredients.

[0022] The active ingredient refers to a compound with a tumor treatment function. In the pharmaceutical composition, the polypeptide that specifically binds to SLUG to inhibit ZNF451 and promotes CCL5 transcriptional activation can be used alone as an active ingredient or together with other compounds with anti-tumor activity as an active ingredient.

[0023] The administration route of the pharmaceutical composition of the present invention is preferably injection or oral administration. The injection preferably includes intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection or subcutaneous injection. The pharmaceutical composition is in various conventional dosage forms in the art, preferably in the form of solid, semi-solid or liquid, and can be an aqueous solution, non-aqueous solution or suspension, more preferably tablets, capsules, granules, injections or infusions, etc.

[0024] Preferably, the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable carrier or excipient. The carrier or excipient is a conventional pharmaceutical carrier or excipient in the art, and the carrier or excipient can be any suitable physiologically or pharmaceutically acceptable pharmaceutical excipient. The pharmaceutical excipient is a conventional pharmaceutical excipient in the art, preferably including a pharmaceutically acceptable excipient, filler or diluent, etc. More preferably, the pharmaceutical composition comprises 0.01-99.99% of the above-mentioned polypeptide and 0.01-99.99% of a pharmaceutical carrier or excipient, and the percentage is the mass percentage of the pharmaceutical composition.

[0025] Preferably, the amount of the pharmaceutical composition administered is an effective amount, which is an amount that can alleviate or delay the progression of a disease, degenerative or damaging condition. The effective amount can be determined on an individual basis and will be based in part on considerations of the symptoms to be treated and the results sought.

[0026] Beneficial technical effects: The polypeptide PZ of the present invention can inhibit the interaction between ZNF451 and SLUG protein, inhibit the transcription of chemokine CCL5, downregulate the expression level of CCL5, inhibit tumor cell stemness, inhibit tumor cell migration and inhibit tumor cell growth, and is thus applied to the preparation of drugs for treating and preventing tumors. The prepared drugs have the advantages of significant efficacy, few toxic and side effects and safe use in the treatment of tumor diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0028] Figure 1 The results of Western blotting to detect the expression of ZNF451 in tumor tissues in Example 2;

[0029] Figure 2 This is the result of the immunoprecipitation method in Example 3 confirming that ZNF451 interacts with SLUG. DETAILED DESCRIPTION

[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0032] The reagents and raw materials used in the present invention are commercially available.

[0033] The PBS described in the examples refers to a phosphate buffer with a concentration of 0.1 M and a pH value of 7.2.

[0034] The room temperature described in the examples is the conventional room temperature in the art, preferably 15-30°C.

[0035] The experimental results are expressed as mean ± standard error. After comparison with parametric or non-parametric variance test, p < 0.05 is considered to be significantly different, and p < 0.01 is considered to be extremely significantly different.

[0036] Tumor cells (all purchased from the American Type Culture Collection (ATCC)): breast cancer cells (MDA-MB-231), liver cancer cells (HepG-2), lung cancer cells (A549), glioma cells (U87) and colon cancer cells (HCT-8).

[0037] Example 1 Detection of ZNF451 expression in tumor tissues by Western blotting

[0038] Mix RIPA (strong) lysis buffer (Biyuntian Company) and add an appropriate amount of PMSF to make the final concentration of PMSF 1mM. Collect tumor patient samples and adjacent tissues, weigh 20mg of tissue, add 250μl of mixed RIPA (strong) lysis buffer, homogenize the tissue and cells for 30min, collect tissue protein supernatant, centrifuge at 12000rmp, 30min. Collect the same volume of protein supernatant, use BCA protein concentration determination kit (Biyuntian Company) to quantify the total protein concentration, dilute the protein concentration to 3μg / ml, add 5×Loading, and denature the protein for 10min. Take 10μl of protein sample for SDS-polyacrylamide gel electrophoresis. ImageJ software was used to perform gray value statistics on the results of Western experiments. The results are shown in Table 1. ZNF451 expression increases in various tumor tissues.

[0039] Table 1 Expression results of ZNF451 in various tumor tissues

[0040] Tumor name ZNF451 in adjacent tissues Tumor tissue ZNF451 P-value Breast cancer 62646.07 168820.448 0.00131 Lung cancer 43502.513 68813.028 0.04221 Liver cancer 52330.451 77988.191 0.02148 Glioma 65481.706 155814.711 0.00021 Colon cancer 72396.798 107919.563 0.03199

[0041] Example 2 Real-time quantitative PCR detection of the effect of overexpression of ZNF451 on CCL5 transcription

[0042] MDA-MB-231 cells were cultured and transfected with ZNF451 and PcDNA3.1-3×Flag empty plasmids, respectively. Cells were collected 24 hours after transfection. RNA was extracted from the collected cells and the RNA concentration was measured. DNA was obtained by reverse transcription with 500 ng RNA. qPCR was performed using the reverse transcribed DNA as a template and CCL5 and GAPDH as primers.

[0043] qPCR Primers:

[0044] CCL5 forward: CCTGCTGCTTTGCCTACATTGC (SEQ ID NO: 3);

[0045] CCL5 reverse:ACACACTTGGCGGTTCTTTCGG(SEQ ID NO:4);

[0046] GAPDH forward:GTCTCCTCTGACTTCAACAGCG(SEQ ID NO:5);

[0047] GAPDH reverse:ACCACCCTGTTGCTGTAGCCAA (SEQ ID NO: 6).

[0048] The results are as follows Figure 1 As shown, the results showed that overexpression of ZNF451 could upregulate the expression level of CCL5.

[0049] Example 3 Immunoprecipitation confirms that ZNF451 interacts with SLUG

[0050] 3.1 Immunoprecipitation reagents:

[0051] Lysis buffer A: 0.6057 g Tris base, 1.7532 g NaCl, 0.1017 g MgCl2·6H2O, 0.0742 g EDTA, 10 ml glycerol, 10 ml 10% NP40, add deionized water to 150 ml, adjust pH to 7.6 with HCl, make up to 191 ml, mix well, filter through 0.45 μm filter membrane, and store at 4°C.

[0052] Lysis solution B: 200μl 2Mβ-glycerophosphate, 4ml 2.5M NaF, 2ml 8mM NaVO3, 2ml 100mMPMSF, 200μl 1M DTT, 200μl each of 1mg / ml Leu, Pep and Apr, total volume 9ml. The mother solution was stored at -20℃. Before use, thaw the mother solution of each component in solution B, add them to solution A according to the above composition ratio and mix well. Protein A / GPlus-Agarose was purchased from Santa cruz, USA.

[0053] 3.2 Specific operation steps

[0054] Culture 293T tool cells and co-transfect ZNF451-3×Flag and SLUG-GFP plasmids into the cells. Collect the cells 24 hours later. Lyse the cells with immunoprecipitation lysis buffer, harvest about 4-10 mg of total cell protein, and adjust each group of proteins to the same concentration. Take 200 μg of each group of proteins and keep it as cell lysate input as a control.

[0055] Add 2μg DDK antibody or Normal IgG of the same species as DDK antibody to the remaining protein, and add 10μl Protein A / G Plus-Agarose to fully resuspend, and slowly rotate and shake at 4℃ overnight. Centrifuge at 4℃, 3000rpm for 5min, carefully remove the supernatant, and it is better to leave a small amount of supernatant than to absorb Agarose. Add 0.5ml immunoprecipitation wash solution, mix well, let stand in ice bath for 1min, centrifuge at 4℃, 3000rpm for 30sec, and carefully remove the supernatant. Repeat the wash 5 times, and let stand for 5min before the last centrifugation. Carefully remove the supernatant, add 20-30μl 2×SDS gel loading buffer, mix well, denature at 95℃ for 3min, and quickly transfer to an ice bath to cool. Centrifuge at 12000rpm at room temperature for 2min. The supernatant is the precipitated protein sample, and part or all of it is taken for SDS-polyacrylamide gel electrophoresis.

[0056] Western results Figure 2 As shown by Figure 2 It can be seen that ZNF451 interacts with SLUG.

[0057] Example 4 Screening of peptides binding to SLUG protein using surface plasmon resonance

[0058] The I-TASSER website was used to analyze the domains that interacted with SLUG, and it was found that it contained an α-helical peptide. The peptide was synthesized using a peptide solid phase synthesizer, and this process was performed by Beijing Saibaisheng Gene Co., Ltd. Example The entire screening process was carried out in a surface plasmon resonance instrument Biacore T200. The screening method is as follows: the purified protein SLUG (purchased from Beijing Yiqiao Shenzhou Company) was coupled to a CM5 chip (purchased from GE Company) through amino coupling, the unbound protein was washed away at a flow rate of 10μl / min, and the chip surface was equilibrated for 2 hours.

[0059] First, ZNF451 was segmented and truncated into different polypeptide fragments, and peptide fragments were synthesized using a polypeptide solid phase synthesizer, which was performed by Beijing Saibaisheng Gene Co., Ltd. Example The entire screening process was performed in a surface plasmon resonance instrument Biacore T200. The screening method is as follows:

[0060] 200μl peptide fragments of different concentrations (625, 312.5, 156.25, 78.125, 39.0625, 19.5312, 0nM) were automatically injected, and the whole process was carried out at 25°C. The buffer used was HBS-EP buffer (0.01M HEPES, 0.15M NaCl, 3mM EDTA, 0.005% surfactant). The surface test was performed on Biacore T200, and the binding curves of different concentrations of peptides and SLUG were simulated using the built-in analysis software, and a peptide PZ (SEQ ID NO: 1) with strong binding ability to SLUG was obtained:

[0061] Peptide PZ: Thr-Glu-Ala-Ala-Arg-Ile-Cys-Val-Asp-Gln-Trp-Ile.

[0062] KD=8.937E-8, Rmax(RU)=60.

[0063] Example 5 Competitive ELISA method verifies that peptide PZ can compete with the binding of ZNF451 to SLUG protein

[0064] The specific steps are as follows:

[0065] Dilute human SLUG protein and bovine serum albumin (BSA) to 10μl / ml with PBS, add 100μl to each well, and coat the 96-well ELISA plate overnight at 4℃. Wash three times with PBS containing 0.1% Tween-20. Coat the plate with 200μl blocking solution (10% bovine serum PBS) and coat at 37℃ for 2h. Pour out the coating solution, add 200μl of 1μg / ml ZNF451 protein solution accordingly, and incubate at 37℃ for 1h. Wash five times with PBS containing 0.1% Tween-20. Add 100μl blocking solution as a control and 100μl horseradish peroxidase-labeled polypeptide PZ diluted with blocking solution to each well, incubate at room temperature for 1h. Wash six times with PBS containing 0.1% Tween-20. Prepare substrate color development solution (100mmol / L sodium acetate, pH 6.0, add 10μl 30% hydrogen peroxide, 100μg / ml TMB per 50ml buffer), add 100μl to each well, and incubate at room temperature for 5min. Add 50μl 0.1M dilute sulfuric acid to each well to terminate the reaction. The results are shown in Table 2 as the OD450 of the sample well.

[0066] Table 2 Peptides compete for the binding of ZNF451 and SLUG protein

[0067] PZ(ELISA value) BSA (ELISA value) P-value 1.89 0.10 <0.001 2.12 0.14 2.01 0.11

[0068] The results in Table 2 show that PZ can compete for the binding of ZNF451 to SLUG protein.

[0069] Example 6 Real-time quantitative PCR verification of the effect of polypeptide Pep2-PZ on CCL5 mRNA level

[0070] The peptide segment PZ was connected to the cell-penetrating peptide Pep2 (the sequence of Pep2 is HLYVSPW (SEQ ID NO: 2)) to form a new derivative Pep2-PZ. This peptide segment was synthesized by Saibaisheng Gene Technology Co., Ltd. with a purity of >98%.

[0071] Tumor cells: breast cancer cells (MDA-MB-231), liver cancer cells (HepG2), lung cancer cells (A549), glioma cells (U87) and colon cancer cells (HCT-8).

[0072] The specific steps are as follows:

[0073] 1. Cultivate tumor cells. Evenly spread the tumor cells into six-well plates, add 4×105 cells to each well, and culture them in a 37°C incubator overnight until the cells adhere to the wall.

[0074] 2. On the second day, Pep2-PZ was added at a concentration of 4 μM. 24 hours after the addition of the peptide, the cells were harvested and RNA was extracted. The steps of the RNA rapid extraction kit (Shanghai Yishan Biotechnology) were as follows: (1) Aspirate the culture medium and wash once with 1 ml of PBS. (2) Add 500 μl of Lysis Buffer, pipette vigorously 10 times, transfer to an EP tube, and vortex for 10 seconds to fully lyse the cells. (3) Add an equal volume of anhydrous ethanol to the lysed cells and mix thoroughly, then add the liquid to the binding column in the kit. (4) Centrifuge at 4000×g for one minute and discard the liquid. (5) Use 600 μl of Wash Buffer and centrifuge at 12000×g for one minute and discard the liquid. (6) Pour the column once and centrifuge at 12000×g for one minute. (7) Add 30 μl of RNA-free water and centrifuge at 12000×g for one minute. RNA was obtained.

[0075] 3. Then reverse transcribe the extracted RNA into cDNA using a rapid reverse transcription kit (Shanghai Yishan Biotechnology): (1) Take 100ng-2μg total RNA, add 2μl DNase, add water to 16μl, and gently pipette 5-10 times to mix. (2) React at room temperature for 5 minutes and put on ice for later use. (3) Then add 4μl of 5×RT Mix to the above system. (4) Pipette 10 times to mix thoroughly. (5) React at 42℃ for 15 minutes. Dilute 5-10 times as a template for qPCR.

[0076] 4. Design qPCR primers for mouse CCL5 chemokine and mouse GAPDH. Use the cDNA obtained by reverse transcription as a template for qPCR. The qPCR system used is: 10μl KAPA enzyme, 200nM primer, 50ng template, and 8μl water.

[0077] qPCR Primers:

[0078] CCL5 forward:CCTGCTGCTTTGCCTACCTCTC(SEQ ID NO:7);

[0079] CCL5 reverse:ACACACTTGGCGGTTCCTTCGA(SEQ ID NO:8);

[0080] GAPDH forward:CATCACTGCCACCCAGAAGACTG(SEQ ID NO:9);

[0081] GAPDH reverse:ATGCCAGTGAGCTTCCCGTTCAG (SEQ ID NO: 10).

[0082] The results are shown in Table 3-7. The polypeptide Pep2-PZ can reduce the mRNA level of chemokine CCL5.

[0083] Table 3 Peptides inhibit the transcriptional activity of SLUG / CCL5 in MDA-MB-231 cells

[0084]

[0085] Table 4 Peptides inhibit the transcriptional activity of SLUG / CCL5 in HepG2 cells

[0086] Control peptide (qPCR value) Pep2-PZ-4μM (qPCR value) P-value 1 0.38 0.0058 1.10 0.25 0.74 0.36

[0087] Table 5 Peptides inhibit the transcriptional activity of SLUG / CCL5 in A549 cells

[0088] Control peptide (qPCR value) Pep2-PZ-4μM (qPCR value) P-value 1 0.32 0.0003 0.96 0.22 0.88 0.37

[0089] Table 6 Peptides inhibit the transcriptional activity of SLUG / CCL5 in U87 cells

[0090] Control peptide (qPCR value) Pep2-PZ-4μM (qPCR value) P-value 1 0.45 0.0012 1.25 0.28 1.05 0.33

[0091] Table 7 Peptides inhibit the transcriptional activity of SLUG / CCL5 in HCT-8 cells

[0092]

[0093] Example 7 Oris Cell Migration Detection Kit Verifies the Effect of Pep2-PZ on Tumor Cell Migration Ability

[0094] Tumor cells: breast cancer cells (MDA-MB-231), liver cancer cells (HepG2), lung cancer cells (A549), glioma cells (U87) and colon cancer cells (HCT-8).

[0095] 1. Remove the Oris with cell seeding plug from the refrigerator. TM TriCoated plate and place it on the lab bench for approximately 1 hour to allow it to equilibrate to room temperature.

[0096] 2. Visually inspect the underside of the filled 96-well plate to ensure that Oris TM The cell seeding plugs seal securely to the bottom of the plate. To check the stopper, flip the plate over and inspect the stopper for a seal. If an incomplete seal is observed, return the plate to a vertical position and use a sterile instrument to gently push the stopper back into the well until a seal is observed.

[0097] 3. If you are collecting microplate reader data, apply Oris TM Detection Mask. If you collect imaging data, you do not need a detection mask.

[0098] 4. If you are performing kinetic analysis of cell migration, pre-label the cells with fluorescent staining now.

[0099] 5. Collect the cells and prepare a suspension with a density 10 times higher than the optimal seeding concentration.

[0100] 6. Use a pipette to transfer 100 μl of the suspended cells through the Oris TM Move one side port of the cell seeding plug into each test well.

[0101] 7. Gently tap the plate on the work surface to evenly distribute the contents of the wells.

[0102] 8. Cultivate Oris TM Incubate the seeded plates in a humidified chamber (37 °C, 5% CO 2 ) for 4 to 18 h (cell line dependent and surface treatment dependent) to allow cells to attach.

[0103] 9. Remove the culture plate from the incubator.

[0104] 10. Designate several "reference" wells for each surface treatment where the plug will remain in place until the results are read (t=0 pre-migration control).

[0105] 11. Use OrisTM Stopper tool, remove all other stoppers. Secure the 96-well plate firmly to the deck of the work area. TM The spring teeth of the stop tool slide under the stem of the stop bar, allowing the Oris TM The bottom surface of the stop tool is flush with the top surface of the plate. Lift the Oris vertically TM Stop tool, gently remove the stop.

[0106] 12. Remove the medium with a pipette and gently wash the wells with 100 μl of sterile PBS (or medium) to remove any unattached cells. Do not use the internal vacuum to aspirate.

[0107] 13. Add 100 μl of fresh culture medium to each well.

[0108] 14. Place the culture plate in a humidified chamber (37°C, 5% CO 2 ) to allow cell migration. Cells can be examined microscopically throughout the incubation period to monitor the progress of migration. Migration times will vary depending on cell type, experimental design, and surface treatment, as different extracellular matrices have different effects on migration (even for a given cell line).

[0109] 15. Perform endpoint analysis on cell migration and use fluorescent staining after cells have migrated sufficiently.

[0110] The results are shown in Tables 8-12, which show that the polypeptide Pep2-PZ can significantly reduce the migration rate of tumor cells.

[0111] Table 8 Peptide Pep2-PZ inhibits tumor cell migration in MDA-MB-231

[0112] Control peptide (mobility) Pep2-PZ-4μM (mobility) P-value 87.56 45.12 0.0005 82.12 34.12 88.23 31.25

[0113] Table 9 Peptide Pep2-PZ inhibits tumor cell migration in HepG2

[0114] Control peptide (mobility) Pep2-PZ-4μM (mobility) P-value 83.32 30.11 0.0003 85.45 43.56 84.18 33.64

[0115] Table 10 Peptide Pep2-PZ inhibits tumor cell migration in A549

[0116] Control peptide (mobility) Pep2-PZ-4μM (mobility) P-value 79.43 49.44 0.002 72.53 42.67 82.70 34.32

[0117] Table 11 Peptide Pep2-PZ inhibits tumor cell migration in U87

[0118] Control peptide (mobility) Pep2-PZ-4μM (mobility) P-value 83.35 37.09 0.003 83.89 55.87 87.12 48.80

[0119] Table 12 Peptide Pep2-PZ inhibits tumor cell migration in HCT-8

[0120] Control peptide (mobility) Pep2-PZ-4μM (mobility) P-value 77.60 30.30 0.0004 83.01 37.14 87.10 40.90

[0121] Example 8 Cell spheroidization experiment verifies the effect of polypeptide Pep2-PZ on tumor cell stemness

[0122] Specific operation steps: Breast cancer cells (MDA-MB-231), liver cancer cells (HepG-2), lung cancer cells (A549), glioma cells (U87) and colon cancer cells (HCT-8) were collected. The cells were seeded on 96-well ultra-low attachment plates (Corning) at a density of 500 cells / well and cultured in serum-free tumor sphere medium containing peptide Pep2-PZ (R&D, CCM012). Images were obtained by observation under a microscope (Olympus Microsystems), and the number of spheres was counted after 5-7 days.

[0123] The results are shown in Table 13, which show that the polypeptide Pep2-PZ can reduce the stemness of tumor cells.

[0124] Table 13 Peptide Pep2-PZ inhibits the colony formation of tumor cells.

[0125] Cell Name Control peptide (clone number) Pep2-PZ-4μM (clone number) P-value MDA-MB-231 69±4.00 24.67±2.44 0.00013 HepG2 78.8267±2.22 26.33±3.10 0.00006 A549 83±3.33 34±3.33 0.00013 U87 79.67±4.44 32.67±4.44 0.00080 HCT-8 77±8 35±6.67 0.00678

[0126] Example 9 Tumor subcutaneous growth experiment verifies that the polypeptide inhibits the growth of tumor cells in mice

[0127] Tumor cells: breast cancer cells (MDA-MB-231), liver cancer cells (HepG-2), lung cancer cells (A549), glioma cells (U87) and colon cancer cells (HCT-8).

[0128] Experimental consumables and reagents: sterile EP tube 1.5ml, sterile 10ml centrifuge tube, gun tip filter (100 mesh), absorbent cotton balls, several tweezers, alcohol cotton balls, sterile 1ml syringe, matrigel, PBS (filtered), trypsin, serum.

[0129] Experimental animals and groups: 20 male nude mice aged 4-6 weeks (purchased from Beijing Sibeifu Experimental Animal Co., Ltd.) were randomly divided into two groups: a control group of 7 mice and a polypeptide PZ administration group of 7 mice.

[0130] Cell preparation: Digest the tumor cells cultured on the wall with trypsin. After the trypsin digestion time is reached (the cells should be in single cell state and just adhere to the wall without falling off), remove the trypsin. Use PBS containing 1% serum at 2ml / dish to stop, blow off the cells, transfer to a 10ml centrifuge tube, and centrifuge at 1000g for 5min. Discard the supernatant, resuspend in PBS, and filter through a 100-mesh filter once; count the cells, mix with matrigel at a ratio of cells: matrigel = 1:1, and adjust the final cell concentration to 4×105 / ml.

[0131] Tumor cell inoculation: 100 μl of cell suspension was inoculated subcutaneously in the right upper abdomen near the armpit of nude mice.

[0132] Tumor growth observation: One week after in situ injection of tumor cells, the patient was treated with polypeptide (4 mg / kg body weight, once every other day). The tumor size was recorded with a vernier caliper. Tumor volume = (length × width × width) / 2.

[0133] The experimental results are expressed as mean ± SEM, and the difference between the polypeptide group and the control group is tested by t-test. Four weeks after tumor inoculation, the tumor volume of mice in each group is shown in Table 14-Table 18. The larger the tumor volume, the faster the tumor grows. Therefore, the polypeptide Pep2-PZ can inhibit the growth of tumor cells in mice.

[0134] Table 14 Peptides inhibit the growth of breast cancer cells MDA-MB-231 in mice

[0135] Peptide name <![CDATA[Tumor volume (mm 3 )]]> P-value Comparison 1872.3±156.2 Pep2-PZ 756.5±97.4 <0.001

[0136] Table 15 Peptides inhibit the growth of liver cancer cells HepG2 in mice

[0137] Peptide name <![CDATA[Tumor volume (mm 3 )]]> P-value Comparison 1599.0±106.2 Pep2-PZ 1035.9±67.5 <0.001

[0138] Table 16 Peptides inhibit the growth of lung cancer cells A549 in mice

[0139] Peptide name <![CDATA[Tumor volume (mm 3 )]]> P-value Comparison 1141.4±196.3 Pep2-PZ 491.3±99.2 <0.001

[0140] Table 17 Peptides inhibit the growth of glioma cells U87 in mice

[0141] Peptide name <![CDATA[Tumor volume (mm 3 )]]> P-value Comparison 1528.628±134.4 Pep2-PZ 892.57±126.24 <0.001

[0142] Table 18 Peptides inhibit the growth of colon cancer cells HCT-8 in mice

[0143] Peptide name <![CDATA[Tumor volume (mm 3 )]]> P-value Comparison 1465.58±205.77 Pep2-PZ 737.56±97.96 <0.001

[0144] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention. Sequence Listing <110> Institute of Materia Medica, Chinese Academy of Medical Sciences <120> Polypeptide for targeted inhibition of SLUG transcriptional activation and use thereof <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 12 <212> PRT <213> Human <400> 1 Thr Glu Ala Ala Arg Ile Cys Val Asp Gln Trp Ile 1 5 10 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <400> 2 His Leu Tyr Val Ser Pro Trp 1 5

Claims

1. A polypeptide capable of specifically binding to SLUG and a polypeptide derivative thereof, characterized in that: The amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO: 1; the polypeptide derivative is a chimeric peptide formed by connecting the polypeptide and a cell-penetrating peptide, and the cell-penetrating peptide is the amino acid sequence shown in SEQ ID NO:

2.

2. The polypeptide and polypeptide derivatives thereof according to claim 1, characterized in that: The N-terminus or C-terminus of the polypeptide is connected to a cell-penetrating peptide to obtain the chimeric peptide.

3. A pharmaceutical composition, characterized in that The pharmaceutical composition contains the polypeptide and polypeptide derivatives thereof according to any one of claims 1 to 2 and a pharmaceutically acceptable carrier or excipient.

4. Use of the polypeptide and polypeptide derivatives thereof according to any one of claims 1 to 3 in the preparation of drugs for treating cancer, wherein the cancer is breast cancer, liver cancer, lung cancer, glioma or intestinal cancer.